Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.

      Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG
                            Pharmaceuticals, Inc.

PR Newswire

NEW YORK, Jan. 22, 2014

NEW YORK, Jan. 22, 2014 /PRNewswire/ --Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the securities of
AMAG Pharmaceuticals, Inc. ("AMAG Pharmaceuticals" or the "Company")
(NasdaqGS: AMAG -News). The investigation focuses on whether the Company and
its executives complied with federal securities laws.

On January 22, 2014, shares of AMAG Pharmaceutical fell $1.36 or 6.22% during
intraday trading to trade at $20.50 after the Company announced that the FDA
has issued a complete response letter for the supplemental new drug
application for Feraheme (ferumoxytol) injection for intravenous use. The sNDA
sought to expand the indication for Feraheme beyond the current chronic kidney
disease indication to include all adult iron deficiency anemia (IDA) patients
who have failed or cannot tolerate oral iron treatment. In the letter, the
FDA stated that AMAG has not provided sufficient information to permit
labeling of Feraheme for safe and effective use for the proposed indication.
The FDA indicated that its decision was based on the cumulative ferumoxytol
data, including the global phase III IDA program and global post-marketing
safety reports. The FDA suggested that AMAG generate additional clinical trial
data in the proposed broad IDA patient population with a primary composite
safety endpoint of serious hypersensitivity/anaphylaxis, cardiovascular
events, and death.

If you are aware of any facts relating to this investigation, or purchased
shares of AMAG Pharmaceuticals, you can assist this investigation by
contacting Peretz Bronstein or his Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email Those who inquire by e-mail are encouraged to include their
mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484

SOURCE Bronstein, Gewirtz & Grossman, LLC

Press spacebar to pause and continue. Press esc to stop.